Clinical trials recruiting for Lupus

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• " TREX1 Gene Mutations and Their Role in Systemic Lupus Erythematosus
  NCT07397728 · Phase: Not specified · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• 2-HOBA in Systemic Lupus Erythematosus
  NCT07225543 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus
  NCT07339332 · Phase: Early Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
  NCT06106906 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus
  NCT06106893 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
  NCT07444307 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 3 locations
• A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
  NCT07363590 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 21 locations
• A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
  NCT07413341 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
  NCT07104721 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
  NCT06978647 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus
  NCT06943937 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
  NCT07123519 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus
  NCT07509892 · Phase: Phase 2 · Ages: 18 Years to 74 Years · Sex: All (male and female) · 35 locations
• A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
  NCT07403188 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
  NCT07260877 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 32 locations
• A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
  NCT06308978 · Phase: Phase 1 · Ages: 12 Years to 70 Years · Sex: All (male and female) · 21 locations
• A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)
  NCT07491900 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
  NCT06557265 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 19 locations
• A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants
  NCT06625671 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 7 locations
• A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
  NCT07011043 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 18 locations
• A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
  NCT07564596 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
  NCT06570798 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 58 locations
• A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
  NCT06419205 · Phase: Phase 2 · Ages: 16 Years and older · Sex: All (male and female) · 2 locations
• A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
  NCT07570862 · Phase: Phase 2 · Ages: 12 Years to 70 Years · Sex: All (male and female) · 9 locations
• A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus
  NCT07405970 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis
  NCT07229742 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
  NCT07328581 · Phase: Phase 2 · Ages: 16 Years to 70 Years · Sex: All (male and female) · 4 locations
• A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
  NCT07201129 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 14 locations
• A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
  NCT06925542 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 16 locations
• A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
  NCT06411249 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 114 locations
• A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
  NCT07175285 · Phase: Not specified · Ages: 16 Years and older · Sex: All (male and female) · 66 locations
• A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
  NCT06182969 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: Female · 1 location
• A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
  NCT06249438 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
  NCT07193810 · Phase: Early Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
  NCT06613360 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 20 locations
• A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)
  NCT07311200 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Study of E6742 in Participants With Systemic Lupus Erythematosus
  NCT07515014 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 54 locations
• A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
  NCT07332481 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 18 locations
• A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
  NCT07355218 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 36 locations
• A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus
  NCT06857214 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of GR1803 in Systemic Lupus Erythematosus
  NCT07348055 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
  NCT06576271 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 28 locations
• A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
  NCT07371468 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 19 locations
• A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
  NCT07115745 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations
• A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
  NCT06535412 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)
  NCT06917742 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 3 locations
• A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus
  NCT06653556 · Phase: Early Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)
  NCT07331272 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 5 locations
• A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
  NCT07276958 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 9 locations
• A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
  NCT07438496 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 249 locations
• A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
  NCT06980597 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis
  NCT06406205 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 10 locations
• A Study of Quinacrine in Participants With Cutaneous Lupus Erythematosus
  NCT07694336 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
  NCT06581198 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 101 locations
• A Study of SCTB35 in Patients with Systemic Lupus Erythematosus
  NCT06841042 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 14 locations
• A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus
  NCT07299422 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• A Study of Telitacicept in Lupus Nephritis
  NCT05680480 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 45 locations
• A Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy Adults
  NCT07749651 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
  NCT07607964 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 10 locations
• A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
  NCT06977724 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 11 locations
• A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus
  NCT07323173 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 12 locations
• A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
  NCT06875960 · Phase: Phase 4 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 4 locations
• A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
  NCT07598396 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
  NCT06617325 · Phase: Phase 3 · Ages: 16 Years and older · Sex: All (male and female) · 242 locations
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
  NCT05039619 · Phase: Phase 2 · Ages: 5 Years to 17 Years · Sex: All (male and female) · 43 locations
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
  NCT07038382 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 17 locations
• A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases
  NCT06647069 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 6 locations
• A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
  NCT07430306 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 107 locations
• A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
  NCT06916806 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 37 locations
• A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
  NCT07085104 · Phase: Phase 1 · Ages: 18 Years to 74 Years · Sex: All (male and female) · 17 locations
• A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
  NCT06897930 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 20 locations
• A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
  NCT07409181 · Phase: Phase 2 · Ages: 18 Years to 74 Years · Sex: All (male and female) · 140 locations
• AGR+PNI as Predictors of Systemic Lupus Erythematosus Disease Activity
  NCT07043153 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.
  NCT07330245 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 22 locations
• Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
  NCT07507201 · Phase: Early Phase 1 · Ages: 3 Years and older · Sex: All (male and female) · 1 location
• Allogeneic UCB-derived CAR-T for SLE
  NCT07274059 · Phase: Early Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Alnuctamab for Refractory SLE (LATTE Study)
  NCT07219563 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
  NCT06379646 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
  NCT05835310 · Phase: Phase 3 · Ages: 5 Years to 17 Years · Sex: All (male and female) · 100 locations
• An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus
  NCT06010472 · Phase: Early Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases
  NCT06503224 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
  NCT07236762 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
  NCT07174843 · Phase: Early Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Anifrolumab Malignancy and Serious Infections Study
  NCT07000110 · Phase: Not specified · Ages: 18 Years to 130 Years · Sex: All (male and female) · 4 locations
• Anifrolumab Pregnancy Study
  NCT07049653 · Phase: Not specified · Ages: 18 Years to 130 Years · Sex: Female · 1 location
• Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases
  NCT07121777 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322)
  NCT05193591 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases
  NCT06685042 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
  NCT06585514 · Phase: Phase 1, Phase 2 · Ages: 3 Years to 65 Years · Sex: All (male and female) · 1 location
• Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
  NCT06614270 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
  NCT06792799 · Phase: Early Phase 1 · Ages: 3 Years and older · Sex: All (male and female) · 1 location
• Argentinian Prospective Registry of Patients With Lupus
  NCT05470569 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Assessing Residual Inflammation and Macrophage Presence in Lupus Nephritis After 3 Months of Intensified Treatment With Prednisolone, Mycofenolate Mofetil and Voclosporin as Compared to Mycofenolate Mofetil and Prednisolone
  NCT07760480 · Phase: Phase 4 · Ages: 16 Years to 70 Years · Sex: All (male and female) · 1 location
• Assessment of Hematologic Indices in Juvenile Lupus Erythematosus Patients:Correlation With Disease Activity and Chronic Organ Damage in These Patients
  NCT06718283 · Phase: Not specified · Ages: Up to 18 Years · Sex: All (male and female) · 1 location
• Assessment of Physician Consideration of EPRO's, from Patients with Gout, Rheumatoid Arthritis, Sjogren's Syndrome or Systemic Lupus, on the Frequency of Therapeutic Adjustments
  NCT05927688 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Autologous CD19 Car T-Cell Therapy For Severe Refractory Systemic Lupus Erythematosus (SLE)
  NCT06710717 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
  NCT07361094 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 2 locations
• Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
  NCT05029336 · Phase: Phase 2 · Ages: 8 Years to 25 Years · Sex: All (male and female) · 1 location
• BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
  NCT06340750 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
  NCT06794008 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations

Related conditions

Trials recruiting for Lupus often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Lupus trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.